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AIMS AND SCOPE 
 
 
Aims and Scope 
The journal is dedicated to highlighting the most important 
scientific advances in Parkinson’s disease research 
spanning the motor and non-motor disorder of Parkinson’s 
disease. npj Parkinson’s Disease publishes original basic 
science, translational and clinical Research Articles, 
Reviews, Commentaries, Editorials, Brief Communications, 
Correspondence, and Meeting Reports related to 
Parkinson’s disease, including anatomy, etiology, genetics, 
cellular and molecular physiology, neurophysiology, 
epidemiology, and therapeutic development and treatments.  
The journal also publishes a professionally written Editorial 
Lay Summary to accompany each Article, which will 
summarize the key issues being addressed within the article 
aimed to keep readership at the vanguard of new 
discoveries in the field. As an open access journal, npj 
Parkinson’s Disease will be freely and immediately 
accessible to all members of the scientific and Parkinson’s 
disease community. 
 
Relationship to other Nature journals 
npj Parkinson’s Disease is a new open access, online-only, 
Nature Research journal published by Springer Nature in 
partnership with Parkinson’s Disease Foundation (PDF). 
 
npj Parkinson’s Disease is editorially independent. The 
editors make their own decisions, independently of the other 
Nature Research journals.  
 
If a paper is rejected from one Nature Research journal, the 
authors can use an automated manuscript transfer service 
to submit the paper to another journal via a link sent to them 
by the editor handling the manuscript.  
 
In cases where manuscripts are rejected from npj 
Parkinson’s Disease, authors may wish to use the same 
manuscript transfer service to submit their paper to other 
Nature Research journals.  
 
For more information, please consult the following: 
Details of the manuscript transfer service 
Listing of all Nature journals 
 
Journal Details 
 
Editors-in-Chief:   
David Sulzer, PhD, Columbia University, New York, USA 
 
K Ray Chaudhuri, MD FRCP DSc, Kings College London, 
UK 
 
Advisory Editor 
Stanley Fahn, MD, Columbia University, New York, USA 
 
Editorial Office:  
Springer Nature, New York, USA 
Email: npjparkd@nature.com 
Phone: +1 212 726 9387 
 
 
 
 
 
 
 
 
 
 
 
ARTICLE TYPE SPECIFICATIONS 
 
Article Description Abstract  Word Limit Tables/ 
Figures 
References 
Article  
A complete, comprehensive report of original 
research. An Article usually has a fairly complex 
narrative that is based on multiple techniques 
and/or approaches. 
Unstructured abstract; 
max word limit: 250 
5,000 words 
excluding 
abstract, 
references, 
figures and tables 
Max of 6  Max of 50. 
Please use 
as current 
as possible. 
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Brief Communication 
A concise report of research of high quality and 
broad interest to a journal’s target audience. 
Usually a short report of interim work or final 
report of research that does not warrant a full 
research paper publication. 
Unstructured abstract; 
max word limit: 150 
800 words 
excluding 
references 
Max of 2 Max of 10 
Correspondence  
The Editors will occasionally consider the 
publication of correspondence developing the 
debate relating to a particular journal article that 
has already been published. These pieces are 
not applicable for an Article Processing Charge. 
The Correspondence should be received within 
6 weeks after publication of the journal article to 
which it refers. 
None 350 words max 
excluding, 
references, 
figures and tables 
None Max of 5, 
not 
including 
reference to 
the original 
article. 
Case Report 
The Editors welcome submission of patient-
oriented evidence-based case reports. A 
Discussion section should highlight the 
educational nature of the case(s) being 
presented. 
 
Unstructured abstract; 
max word limit: 250 
2,000 words 
excluding 
abstract, 
references, 
figures and tables 
Max of 2 Max of 50 
Editorial 
An authoritative timely opinion on an issue or a 
paper; it is usually written or invited by the 
Editor-in-Chief. 
 
None 1,000 words 
excluding 
references 
Max of 2 Max of 15 
Meeting Report 
An account of proceedings at a recent 
conference of broad interest to the target 
readership of the journal. 
 
Unstructured abstract; 
max word limit: 150 
Maximum of 
2,000 words 
excluding 
abstract, 
references, 
figures and tables 
Max of 2 Max of 50 
Perspective 
It should provide an evidence-based opinion on 
a particular article or subject. There should be a 
short introduction, followed by relevant section 
headings and a conclusions’ section at the end. 
The standard footer headings 
(Acknowledgements, Contributions, Competing 
Interests, Funding) are required. 
 
Unstructured abstract; 
max word limit: 250 
2,000 words 
excluding 
abstract, 
references, 
figures and tables 
Max of 3 Max of 50 
Review  
A comprehensive synthesis and/or analysis of 
specific topics. A short Introduction giving the 
rationale for the review should be followed by 
sections with appropriate subheadings, 
followed by a conclusions section at the end. 
The standard footer headings 
(Acknowledgements, Contributions, Competing 
Interests, Funding) are required. All invited 
reviews will undergo peer review prior to 
acceptance. 
 
Unstructured abstract; 
max word limit: 250 
 
5,000 words 
excluding 
abstract, 
references, 
figures and tables 
Max of 8 Max of 100 
 
Word limit 
Word limits are provided for guidance only. The Editors will consider submissions that exceed the recommended limit, subject to 
feedback received during peer review. 
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PREPARATION OF ARTICLES 
 
 
Papers submitted for consideration in npj Parkinson’s 
Disease can be in any standard format accepted by other 
journals in the field, as long as all the elements cited below 
are included. 
 
Articles accepted for publication in npj Parkinson’s Disease 
must contain the following components in the order stated, 
please see below for further details. 
 
 Title page 
 Abstract and keywords 
 Introduction 
 Results 
 Discussion  
 Methods 
 Acknowledgements 
 Competing Interests 
 Contributions 
 Funding 
 References 
 Figure legends 
 Tables 
 Figures 
 
Cover Letter: The uploaded cover letter must state the 
material is original, has not been previously published in 
another peer-reviewed journal and has not been submitted 
for publication elsewhere while under consideration. A 
Competing Interests statement should also be included. 
 
Manuscript text: All textual content is provided in a single 
file, prepared using either Word or TeX/LaTeX; figures are 
provided in individual files.  
 
Word: Nature Partner Journals do not use a manuscript 
template for Word documents. The manuscript file should 
be formatted as double spaced, single-column text without 
justification. Pages should be numbered using an Arabic 
numeral in the footer of each page. Standard fonts are 
recommended and the 'symbols' font should be used for 
representing Greek characters.  
 
TeX/LaTeX: Authors submitting LaTeX files may use any of 
the standard class files such as article.cls, revtex.cls or 
amsart.cls. Non-standard fonts should be avoided; please 
use the default Computer Modern fonts. For the inclusion of 
graphics, we recommend graphicx.sty. Please use 
numerical references only for citations. There is no need to 
spend time visually formatting the manuscript: journal style 
will be imposed when the paper is prepared for publication. 
References should be included within the manuscript file 
itself.  
 
BibTeX bibliography files: Authors who wish to use 
BibTeX to prepare their references should therefore copy 
the reference list from the .bbl file that BibTeX generates 
and paste it into the main manuscript .tex file (and delete 
the associated \bibliography and \bibliographystyle 
commands). As a final precaution, authors should ensure 
that the complete .tex file compiles successfully on their 
own system with no errors or warnings, before submission. 
Title Page: The title page should bear the title of the paper, 
the full names of all the authors and their affiliations, 
together with the name, full postal address, telephone and 
e-mail address of the author to whom all correspondence is 
to be addressed.  
 The title should be brief, informative, of 150 characters 
or less.  
 The running title should consist of no more than 50 
letters and spaces. It should be as brief as possible, 
convey the essential message of the paper and 
contain no abbreviations.  
 Authors should disclose the sources of any support for 
the work, received in the form of grants and/or 
equipment and drugs. 
 If authors regard it as essential to indicate that two or 
more co-authors are equal in contribution status, they 
may be identified by an asterisk symbol with the 
caption ‘These authors contributed equally to this 
work’ immediately under the address list. 
 
Abstract: Abstracts should be unstructured and of no more 
than 250 words. 
 
Introduction: The Introduction should assume that the 
reader is knowledgeable in the field and should therefore be 
as brief as possible, but can include a short background 
description/overview where desirable. 
 
Results: The Results section should briefly present the 
experimental data in text, tables or figures. Tables and 
figures should not be described extensively in the text. 
Section sub-headings can be used to aid clarity. 
 
Discussion: The discussion should focus on the 
interpretation and the significance of the findings with 
concise objective comments that describe their relationship 
to other work in the area. It should not repeat information in 
the results section.  
 
Methods: This section should contain sufficient detail, so 
that all experimental procedures can be reproduced, and 
include references. However, methods that have been 
published in detail elsewhere should not be described in 
detail. Authors should provide the name of the manufacturer 
for any specifically named equipment and instruments; if 
applicable, all drugs should be identified by their 
pharmaceutical names, and by their trade name if relevant. 
Section sub-headings should be used to aid clarity. 
 
Availability of data, materials and methods: An inherent 
principle of publication is that others should be able to 
replicate and build upon the authors' published claims. A 
condition of publication is that authors are required to make 
materials, data, code, and associated protocols promptly 
available to readers without undue qualifications.  
 
Submission of a manuscript to npj Parkinson’s Disease 
implies that materials described in the manuscript, including 
all relevant raw data, will be freely available to any scientist 
wishing to use them for non-commercial purposes, without 
breaching participant confidentiality.  
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Data availability statements: Data availability statements 
provide a statement about where data supporting the results 
reported in a published article can be found - including, 
where applicable, hyperlinks to publicly archived datasets 
analysed or generated during the study. We encourage the 
provision of data availability statements, examples and 
details can be seen on our data policy web page. The 
statement should be placed at the end of the Methods 
section (titled, ‘Data availability’), after the code availability 
statement if one is present. For further guidance, please 
refer to the Data availability and data citations policy 
information and Frequently Asked Questions (FAQs). 
 
npj Parkinson’s Disease strongly encourages that all 
datasets on which the conclusions of the paper rely should 
be available to readers. We encourage authors to ensure 
that their datasets are either deposited in publicly available 
repositories (where available and appropriate) or presented 
in the main manuscript or additional supporting files 
whenever possible. Please see Springer Nature’s 
information on recommended repositories. General 
repositories - for all types of research data - such as 
figshare and Dryad may be used where appropriate.  
 
Where a widely established research community 
expectation for data archiving in public repositories exists, 
submission to a community-endorsed, public repository is 
mandatory. Persistent identifiers (such as DOIs and 
accession numbers) for relevant datasets must be provided 
in the paper. 
 
Acknowledgements: These should be brief and should 
include sources of support including sponsorship (e.g., 
university, charity, commercial organisation) and sources of 
material (e.g., novel drugs) not available commercially. 
 
Contributions: The exact role(s) of each author should be 
included in the declaration. For research manuscripts, one 
or more of the authors should be identified as the guarantor. 
Only those who have made substantial contributions to the 
study and/or preparation of the manuscript should be 
acknowledged as authors and named in full.  
 
Competing Interests: Authors must declare whether or not 
there are any competing interests in relation to the work 
described. This information must be included at this stage 
and will be published as part of the paper. Conflict of 
interest should be noted in the cover letter and in the paper. 
Please see the Conflict of Interest documentation in the 
Editorial Policy section for detailed information. 
 
Funding: Authors should declare the source of funding for 
their research, if applicable. 
 
References: All necessary references should be included in 
order to credit previous work directly relevant to the article. 
This should translate to a number of references within the 
range described in the article type specification section. 
References should follow the Nature style available in most 
reference management software. In the text they should 
appear as superscript numbers starting at 1 and at the end 
of the paper they should be listed (double-spaced) in 
numerical order corresponding to the order of citation in the 
text. Where a reference is to appear next to a number in the 
text, for example, following an equation, chemical formula or 
biological acronym, citations should be written as (ref. X) 
and not as superscript. Example: “detectable levels of 
endogenous Bcl-2 (ref. 3), as confirmed by western blot.” 
 
All authors should be listed for papers with up to five 
authors; for papers with more than five authors, the first only 
should be listed, followed by et al. Abbreviations for titles of 
medical periodicals should conform to those used in the 
latest edition of Index Medicus. The first and last page 
numbers for each reference should be provided. Abstracts 
must be identified as such. Papers in press and preprints 
hosted on a recognized server may be included in the list of 
references. 
 
Personal communications must be allocated a number and 
included in the list of references in the usual way or simply 
referred to in the text; the authors may choose which 
method to use. In either case authors must obtain 
permission from the individual concerned to quote his/her 
unpublished work. 
Examples: 
Journal article, up to five authors: 
Belkaid, Y. & Rouse, B. T. Natural regulatory T cells in 
infectious disease. Nat. Immunol. 6, 353–360 (2005). 
 
Journal article, e-pub ahead of print: 
Bonin, M. et al. F-ara-A pharmacokinetics during reduced-
intensity conditioning therapy with fludarabine and 
busulfan. Bone Marrow Transplant. 
http://dx.doi.org/10.1038/sj.bmt.1705565 (2007). 
 
Journal article, in press: 
Gallardo, R. L., Juneja, H. S. & Gardner, F. H. Normal 
human marrow stromal cells induce clonal growth of human 
malignant T-lymphoblasts. Int. J. Cell Cloning (in the press). 
 
Complete book: 
Atkinson, K. et al. (eds) Clinical Bone Marrow and Blood 
Stem Cell Transplantation (Cambridge Univ. Press, 2004).  
 
Chapter in book: 
Harley, N. H. & Vivian, L. in Mechanisms of Disease 4th 
edn, Vol. 2 (eds Sodeman, W. A. & Smith, A.) Ch. 3 
(Saunders, 1974). 
 
Abstract: 
Feig, S. A. et al. Bone marrow transplantation for 
neuroblastoma. Exp. Hematol. 13, abstr. 102 (1985). 
 
Preprint: 
Starrfelt, J. & Liow, L.H. How many dinosaur species were 
there? Fossil bias and true richness estimated using a 
Poisson sampling model (TRiPS). Preprint at 
http://biorxiv.org/content/early/2015/12/04/025940 (2015). 
 
Research dataset: 
Hao, Z., AghaKouchak, A., Nakhjiri, N. & Farahmand, A. 
Global Integrated Drought Monitoring and Prediction System 
(GIDMaPS) Data sets. figshare. 
http://dx.doi.org/10.6084/m9.figshare.853801 (2014). 
 
Figure Legends: These should be brief, specific and 
appear on a separate manuscript page after the References 
section.  
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Tables: These should be labelled sequentially and cited 
within the text. Each table should be presented on its own 
page, numbered and titled. Reference to table footnotes 
should be made by means of Arabic numerals. Tables 
should not duplicate the content of the text. They should 
consist of at least two columns; columns should always 
have headings. Authors should ensure that the data in the 
tables are consistent with those cited in the relevant places 
in the text, totals add up correctly, and percentages have 
been calculated correctly. Tables should only be used to 
present essential data. Each must be on a separate sheet 
with a title or caption and be clearly labelled, sequentially. 
Please make sure each table is cited within the text and in 
the correct order, e.g. (Table 3). Tables should ideally be 
presented in Excel, one table per workbook. It is imperative 
that the tables are editable. Please save the files with 
extensions .xls / .xlsx / .ods / or .doc or .docx. Please 
ensure that you provide a 'flat' file, with single values in 
each cell with no macros or links to other workbooks or 
worksheets and no calculations or functions. 
 
Figures: Figures and images should be labelled 
sequentially and cited in the text. Figures should not be 
embedded within the text but rather uploaded as separate 
files. Detailed guidelines for submitting artwork can be found 
by downloading our Artwork Guidelines. The use of three-
dimensional histograms is strongly discouraged when the 
addition of the third dimension gives no extra information.  
 
Supplementary Information: Supplementary information 
(SI) is peer-reviewed material directly relevant to the 
conclusion of an article that is not included within the main 
body of the article. The article must be complete and self-
explanatory without the SI, which is posted on the journal's 
website and linked to the article. SI may consist of data files, 
graphics, movies or extensive tables. Please see our 
Artwork Guidelines for information on accepted file types.  
 
Authors should submit SI files in the FINAL format as they 
are not edited, typeset or changed, and will appear online 
exactly as submitted. When submitting SI, authors are 
required to:  
 Include a text summary (no more than 50 words) to 
describe the contents of each file. 
 Identify the types of files (file formats) submitted. 
 Include the text “Supplementary information is 
available at (journal name)’s website” at the end of the 
article and before the references. 
 
Reporting Tools: Please also ensure that, where relevant, 
the appropriate reporting guidance checklist (e.g. 
CONSORT for randomised controlled trials, PRISMA for 
systematic reviews, and STROBE for cohort, case-control 
and cross-sectional studies) has been completed and 
submitted as a supplementary file. These can be obtained 
from http://www.equator-network.org. 
 
In order to improve the overall transparency of reporting and 
the reproducibility of published results we require that you 
complete and submit the following reporting checklist 
http://www.nature.com/authors/policies/checklist_AJ.pdf. 
 
House Style 
 All pages and lines are to be numbered.  To add page 
numbers in MS Word, go to Insert then Page 
Numbers. To add line numbers go to File, Page Setup, 
then click the Layout tab. In the Apply to box, 
select Whole document, click Line Numbers then 
select the Add line numbering check box, followed by 
Continuous.  
 Use a coarse hatching pattern rather than shading for 
tints in graphs. 
 Colour should be distinct when being used as an 
identifying tool. 
 Units: Use metric units (SI units) as fully as possible. 
Preferably give measurements of energy in kiloJoules 
or MegaJoules with kilocalories in parentheses (1 kcal 
= 4.186kJ). Use % throughout.  
 Abbreviations: On first using an abbreviation place it in 
parentheses after the full item. Very common 
abbreviations such as FFA, RNA, need not be defined. 
Note these abbreviations: gram g; litre l;  
 milligram mg; kilogram kg; kilojoule kJ; megajoule MJ; 
weight wt; seconds s; minutes min; hours h. Do not 
add s for plural units. 
 
Language Editing: npj Parkinson’s Disease is read by 
scientists from diverse backgrounds. In addition, many are 
not native English speakers. Authors should therefore give 
careful thought to how their findings may be communicated 
clearly. Although a shared basic knowledge of biology may 
be assumed, please bear in mind that the language and 
concepts that are standard in one subfield may be 
unfamiliar to non-specialists. Thus, technical jargon should 
be avoided as far as possible and clearly explained where 
its use is unavoidable. Abbreviations, particularly those that 
are not standard, should also be kept to a minimum. The 
background, rationale and main conclusions of the study 
should be clearly explained. Titles and abstracts in 
particular should be written in language that will be readily 
intelligible to any scientist. 
 
Even though no paper will be rejected for poor language, 
non–native English speakers occasionally receive 
feedback from editors and reviewers regarding language 
and grammar usage in their manuscripts. You may wish to 
consider asking a colleague whose native language is 
English to read your manuscript and/or to use a 
professional editing service such as those provided by our 
affiliates Nature Research Editing Service or American 
Journal Experts. Please note that the use of a language 
editing service is not a requirement for publication in npj 
Parkinson’s Disease.
 
HOW TO SUBMIT 
 
Pre-submission Enquiries  
Please submit via our online manuscript submission system. 
 
Online Submission 
We only accept manuscript submission via our online 
manuscript submission system. Before submitting a 
manuscript, authors are encouraged to consult both our 
Editorial Policies and the submission instructions for our 
online manuscript submission system. If you have not 
already done so, please register for an account with our 
online manuscript system. You will be able to monitor the 
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status of your manuscript online throughout the editorial 
process.  
 
Submission of Revisions 
Authors submitting a revised manuscript after review are 
asked to include the following: 
(1) A rebuttal letter, indicating point-by-point how you have 
addressed the comments raised by the reviewers. If 
you disagree with any of the points raised, please 
provide adequate justification in your letter.   
 
(2) A marked-up version of the manuscript that highlights 
changes made in response to the reviewers' comments 
in order to aid the Editors and reviewers. Do not use 
track changes or comments.  
(3) A 'clean' (non-highlighted) version of the revised 
manuscript.
 
 
POST-ACCEPTANCE 
 
 
 
Once a manuscript is accepted, the corresponding author 
must complete and sign a Creative Commons licence and 
Article Processing Charge Payment form on behalf of all 
authors and return it to the editorial office. Failure to 
promptly return the form will result in delay of publication.  
 
Publication 
Publishing Open Access will mean the paper is freely 
accessible online immediately upon publication. By paying 
this charge authors are permitted to post the final, 
published PDF of their article on a website, institutional 
repository or other free public server, immediately on 
publication.   
 
Open access articles are published under a CC BY licence 
(Creative Commons Attribution 4.0 International Licence).  
The CC BY licence is preferred by many research funding 
bodies.  It allows for maximum dissemination and re-use of 
open access materials: users are free to share (copy, 
distribute and transmit) and remix (adapt) the contribution 
including for commercial purposes, providing they attribute 
the contribution in the manner specified by the author or 
licensor (read the full legal code). 
 
The CC BY-NC-ND and CC BY-NC-SA licences are 
available on request: please contact the editorial office on 
acceptance of your article to discuss these options. 
 
Under Creative Commons licences, authors retain 
copyright in their work. Authors should note that some 
funders require papers to be published under a specific 
licence and so should check the funder mandate to ensure 
compliance. 
 
With regards to payment, usual credit terms are 30 days 
from receipt of invoice. Failure to pay your invoice within 
the stated credit term may result in such penalties as 
restrictions on your ability to publish with Springer Nature 
in the future, involvement of a third-party debt collection 
agency and legal proceedings.  
Open Access Waiver 
Please note that some institutions have enacted Open 
Access policies that conflict with our own. If any 
corresponding or contributing authors are from these 
institutions, you will need to provide a waiver from the 
institution of every affected author, which can be obtained 
from the institution. This waiver should be submitted at the 
same time as the Open Access Licence to Publish form.  
 
Proofs  
The corresponding author will receive an e-mail containing 
a URL linking to the proofing site. Proof corrections must 
be returned within 48 hours of receipt. Failure to do so may 
result in delayed publication. Extensive changes cannot be 
made at this stage.  
 
Final Publication  
The final version of the manuscript is published online and 
represents the official version of the manuscript. 
 
Self-Archiving 
Authors are encouraged to submit the final version of the 
accepted, peer-reviewed manuscript to their funding body's 
archive for public release immediately upon publication and 
to deposit the final version on their institution’s repository. 
Authors should cite the publication reference and DOI 
number on any deposited version, and provide a link from it 
to the published article on the Nature Research website. 
 
This policy complements the policies of the US National 
Institutes of Health, the Wellcome Trust and other research 
funding bodies around the world. Springer Nature 
recognises the efforts of funding bodies to increase access 
of the research they fund, and strongly encourages authors 
to participate in such efforts. 
 
 
 
 
 
 
PUBLICATION CHARGES 
 
Article Processing Charge
Authors whose papers are accepted for publication in npj 
Parkinson’s Disease are required to pay an Article 
Processing Charge (APC). 
 
The following charges will apply for all un-solicited articles 
published in npj Parkinson’s Disease (plus VAT where 
applicable): 
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 US UK & RoW Europe Japan China 
Original Article  $2,879 £1,900 €2,555 ¥342,860 RMB 17,958 
Other article types $1,364 £900 €1,210 ¥162,407 RMB 8,506 
 
Upon acceptance of their manuscript it is mandatory for 
authors of articles and reports to complete the Article 
Processing Charge payment form and licence to publish 
form and return them to Springer Nature's production 
department (fax number and email included on form); 
processing of an accepted manuscript can only proceed 
once these forms have been signed and returned. 
 
Please note in regards to payment that usual credit terms 
are 30 days from receipt of invoice. Failure to pay your 
invoice within the stated credit term may result in such 
penalties as restrictions on your ability to publish with 
Springer Nature or in the Journal in the future, involvement 
of a third-party debt collection agency and legal 
proceedings. 
 
Article Processing Charge Waiver policy 
npj Parkinson’s Disease offers APC waivers to authors 
from  HINARI countries. Discretionary APC waivers will be 
considered on a case-by-case basis, and may be granted 
in cases of financial need. All applications for APC waivers 
should be made prior to, or at the point of, manuscript 
submission. To request a waiver please contact us at 
apcwaivers@springernature.com. 
 
 
All decisions to publish are based entirely on editorial 
criteria and the editors and reviewers will not have access 
to the information on the author’s ability to pay the Article 
Processing Charge. Springer Nature is a partner of 
AGORA, HINARI, INASP - you can find more information 
here: http://www.nature.com/info/partners.html 
 
 
Open access funding 
Visit Nature Research’s open access funding page for 
information about research funders and institutions that 
provide funding for open access. 
 
Nature Research also offers an APC support service to 
make it easier for Nature Research authors to discover and 
apply for open access funding. For advice on what funding 
is available to you and help in approaching funders and 
institutions, please contact us at openaccess@nature.com. 
 
For more information about Nature Research's open 
access publishing options and policies, please see our 
open access homepage. 
 
 
 
EDITORIAL POLICIES 
 
Duplicate Publication 
Papers must be original and not published or submitted for 
publication elsewhere. This rule also applies to non-English 
language publications. Springer Nature allows and 
encourages prior publication on recognized community 
preprint servers for review by other scientists before formal 
submission to a journal. The details of the preprint server 
concerned and any accession numbers should be included 
in the cover letter accompanying manuscript submission. 
This policy does not extend to preprints available to the 
media or that are otherwise publicized outside the scientific 
community before or during the submission and 
consideration process. 
 
Permissions 
If a table or figure has been published before, the authors 
must obtain written permission to reproduce the material in 
electronic format from the copyright owner and submit it 
with the manuscript. This follows for illustrations and other 
materials taken from previously published works not in the 
public domain. The original source should be cited in the 
figure caption or table footnote. Permission to reproduce 
material can usually be obtained through the Copyright 
Clearance Center. 
 
Clinical Trials 
As defined by the International Committee of Medical 
Journal Editors (ICMJE), a clinical trial is any research 
project that prospectively assigns human subjects to 
intervention and comparison groups to study the cause-
and-effect relationship between a medical intervention and  
 
a health outcome. A medical intervention is any 
intervention used to modify a health outcome and includes 
but is not limited to drugs, surgical procedures, devices, 
behavioural treatments, and process-of-care changes. A 
trial must have at least one prospectively assigned 
concurrent control or comparison group in order to trigger 
the requirement for registration. Nonrandomised trials are 
not exempt from the registration requirement if they meet 
the above criteria. 
 
When reporting experiments on human subjects, please 
indicate whether the procedures were in accordance with 
the ethical standards of the responsible committee on 
human experimentation (institutional or regional) or with the 
Helsinki Declaration of 1975 (as revised in 1983).  Include 
Institutional Review Board or Animal Care and Use 
Committee approvals. 
 
All clinical trials must be registered in a public registry prior 
to submission. The journal follows the trials registration 
policy of the ICMJE (www.icmje.org) and considers only 
trials that have been appropriately registered before 
submission, regardless of when the trial closed to 
enrolment. Acceptable registries must meet the following 
ICMJE requirements:  
 
 be publicly available, searchable, and open to all 
prospective registrants  
 have a validation mechanism for registration data  
 be managed by a not-for-profit organization  
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The trial registry number for eligible papers will be collected 
during the submission process. 
 
Nature Research endorses the toolkits and guidelines 
produced by the following bodies:  
 
Committee on Publication Ethics 
Good Publication Practice  
Medical Publishing Insights and Practices Initiative 
 
Authorship 
The journal recommends that authorship be based on the 
following four criteria: 
 
 Substantial contributions to the conception or design 
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